Please Wait...

  • +91 22 2783 1455

  • Product background
    CEFOTAXIME

WARNING: CAUTION : PLEASE NOTE :
The content or product detailing is not intended to replace advice from your prescribing doctor or healthcare professional. Lavina Pharma is not responsible for such actions by consumers. For any further information about the product please contact +91 22 2783 1455 and we can provide you the details.

CEFOTAXIME FOR INJECTION USP 1 G


Cefotaxime sodium is indicated for the treatment of the following severe infections when known or thought very likely to be due to organisms that are susceptible to cefotaxime.

▪ Infections of the lower respiratory tract

▪ Infections of the kidneys and urinary tract

▪ Infections of the skin and soft tissue

▪ Genital infections caused by gonococci, particularly when penicillin has failed or is unsuitable

▪ Intra-abdominal infections (including Peritonitis)

▪ Lyme-borreliosis (especially stages II and III)

▪ Acute Meningitis in case of gram-negative microorganisms in combination with another suitable antibiotic




COMPOSITION

Each vial contains:

Cefotaxime Sodium USP 

Equivalent to Cefotaxime 1g


Method of administration: Power for Injection

DOSAGE

Dosage and route of administration should be determined by susceptibility of the causative organisms, severity of the infection, and the condition of the patient. Cefotaxime (cefotaxime for injection) for Injection USP and Dextrose Injection is intended for IV administration after reconstitution.


SIDE EFFECT
1) Easy bruising or bleeding,
2) Unusual tiredness,
3) Uncontrollable movements,
4) Mood changes,
5) Confusion,
6) Seizures,
7) Changes in the amount of urine,
8) Nausea,
9) Vomiting,
10) Loss of appetite,
11) Stomach pain,
12) Yellowing of the eyes or skin,
13) Dark urine, and
14) Fast, slow or irregular heart beat




PRECAUTION

Prescribing Cefotaxime (cefotaxime for injection) for Injection USP and Dextrose Injection in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Cefotaxime (cefotaxime for injection) for Injection USP and Dextrose Injection should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.




PRESENTATION

Cefotaxime for Injection 500 mg and 1 g presentations in 10 ml glass vials closed with rubber stoppers and sealed with aluminium caps.